Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + BCG in High-Risk NMIBC
NCT05943106Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2023
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in non-muscle-invasive bladder cancer (NMIBC), sponsored by AstraZeneca. Started Aug 2023; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05943106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05943106.